Bruce Linton is a legend in the cannabis and psychedelics industries.  He was the CEO of the world's largest cannabis company (Canopy Growth), was the first investor in MindMed, and is Chairman of the Advisory Board at Red Light Holland.   

Bruce joins The Integration Conversation to answer questions like:  

And more!   

Plus, Brom and Bruce talk about Empath Ventures.  

❤️ Help us fund the future of psychedelic medicine at Empath Ventures: 

https://www.empath.vc 

⭐️ Become an Integration Insider and get early access to episodes: 

https://patreon.com/theintegrationco 

🐦 brom on twitter:  

https://twitter.com/therealbrom 

🎇 Clips and other stuff on Instagram:  

https://instagram.com/theintegrationco

Disclaimer / Disclosure:  This is not financial advice.  Brom owns shares in MindMed, Red Light Holland and other psychedelics stocks. 

🍄 Bright Minds Bio is a psychedelics research company focused on novel  psychedelics with shorter trip times and lower risk than traditional  psychedelics.  In this episode of The Integration Conversation, we  discuss the risk of traditional psychedelics, what a 5HT2C agonist is,  Bright Mind's NASDAQ Uplisting, and discuss why Bright Minds might be  undervalued relative to its peers.     

⭐️ Become an Integration Insider and get early access to episodes: 

https://patreon.com/theintegrationco  

🎧 Listen on Spotify and other podcast platforms:  

https://anchor.fm/theintegrationco  

🐦 brom on twitter:  

https://twitter.com/therealbrom  

🎇 Clips and other stuff on Instagram:  

https://instagram.com/theintegrationco  

💌 Email:   

[email protected]   

⏰ Timestamps:  

Disclaimer: This video is not financial advice. Brom holds shares in Bright Minds.

🍄 Josh Bartch is the CEO of Mydecine Innovations Group, a psychedelics company that is researching naturally sourced psychedelic therapeutics targeting PTSD and smoking cessation.  In this episode of The Integration Conversation, Josh joins us for a full hour and tells us about Mydecine's clinical trials, its research on functional mushrooms, and makes his pitch for why Mydecine is undervalued relative to its peers.    

Questions we answer: 

🔥 Invest in Psychedelic Startups with Us 🔥 

go to https://theintegration.co and click on "invest in psychedelic startups"  

The Integration Conversation is a podcast that covers the emerging psychedelics industry from a business perspective, and aims to be your number 1 resource for investing in psychedelics,  psychedelic investing and psychedelic business.  

⛓ All our links:  

https://theintegration.co 

📝 My notes on psychedelic investing:  

https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf   

🎧 Listen on Spotify and other podcast platforms:  

https://anchor.fm/theintegrationco 

🐦 brom on twitter:  

https://twitter.com/therealbrom 

🎇 Clips and other stuff on Instagram:  

https://instagram.com/theintegrationco  

⏰ Timestamps: 

Disclaimer: This video is not financial advice. Brom holds shares in Mydecine and other psychedelic stocks.

What exactly is psychedelic therapy, and what does the research on  psychedelic therapy tell us about its effectiveness?  

In this episode of  The Integration Conversation, Brom provides a description of what  exactly happens during psychedelic therapy, and then goes over the three  most compelling clinical research papers on psychedelic therapy.

Learn about how MDMA can treat Post Traumatic Stress Disorder,  psilocybin can treat depression, and how psilocybin stacks up against  SSRIs like Lexapro.   

👇 studies mentioned in this video    

MDMA for PTSD  https://www.nature.com/articles/s41591-021-01336-3  

Trial of Psilocybin versus Escitalopram for Depression 

https://www.nejm.org/doi/full/10.1056/NEJMoa2032994  

Psilocybin to treat Depression and Anxiety in Cancer patients 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367557/  

Psilocybin for smoking Cessation  

https://files.csp.org/Psilocybin/Johnson2017Smoking.pdf  

Ibogaine for Opioid Dependence  

https://pubmed.ncbi.nlm.nih.gov/28402682/     

In this episode of The Integration Conversion, brom give a broad overview of the psychedelic investing landspace, and addresses come common misconceptions about investing in psychedelics.   

Topics Include:  

⏰ Timestamps: 

I'm experimenting with a weekly livestream format where I respond to  short psychedelic articles / topics that don't warrant an entire video.   Plus I interact with the viewers and answer their questions about any  psychedelic topics.

Doug Drysdale is the CEO of Cybin, a psychedelic research company developing novel delivery systems for psilocybin, next-gen psychedelic  tryptamine molecules and performing studies on human brains under the influence of psychedelics using powerful brain imaging technology.  In this episode of the Integration Conversation, Brom and Doug cover all aspects of Cybin's business, and answer questions like:   

👇👇👇 Links 👇👇👇  

📺 Watch on YouTube:  https://youtu.be/cAsFHlVLpeA

💻 The Integration Co Website:  https:/theintegration.co  

📝 My notes on psychedelic investing:  https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf   

🎧 Listen on Spotify and other podcast platforms:  https://anchor.fm/theintegrationco  

🐦 brom on twitter:  https://twitter.com/therealbrom  

🎇 Clips and other stuff on Instagram:  https://instagram.com/theintegrationco  

💌 Email:   [email protected]  

⏰ Timestamps: 

🍄 Field Trip Health is the largest publicly traded, vertically integrated psychedelics company on the market.  Field Trip has a rapidly growing network of ketamine clinics and is developing novel psychedelic molecules and digital therapeutics.  In this deep dive episode, we interview Ronan Levy, the cofounder and executive chairman of field trip.  Ronan tells us:  

📺 Watch the video on YouTube:  https://youtu.be/8gtyZ8DWwNo

📝 My notes on psychedelic investing:  https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf   

🎧 Listen on Spotify and other podcast platforms:  https://anchor.fm/bromtalks   

🐦 brom on twitter:  https://twitter.com/therealbrom 

🎇 Clips and other stuff on Instagram:  https://instagram.com/bromtalks 

💌 Email:   [email protected]   

Disclaimer:  This video is not financial advice.  Brom holds shares in Field Trip Health, Mind Med, Cybin and Compass Pathways.

Atai Life Sciences is the most highly anticipated psychedelic IPO of 2021.  It has a pipeline of 10 drugs, owns a large piece of Compass Pathways, and is also researching digital therapeutics and brain computer interfaces.  When it IPOs it will likely be the psychedelic company with the largest market cap.  In this episode of Brom Talks, we peek behind the curtain of Atai, and try to see if this valuation is justified.  In doing so, we answer questions like:

Who is Christian Angermayer?  What does Atai's pipeline look like?  What are the implications of Atai's unorthodox corporate structure?  It is even fair to call Atai a psychedelics company?  And we also compare and contrast this company with MindMed.   

📝 My notes on psychedelic investing: 

https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf 

🎧 Listen on Spotify and other podcast platforms: 

https://anchor.fm/bromtalks 

📺YouTube:

https://www.youtube.com/c/bromtalks

🐦 brom on twitter: 

https://twitter.com/therealbrom

🎇 Clips and other stuff on Instagram: 

https://instagram.com/bromtalks

💌 Email:  

[email protected]

🍄 Wondering how to tell if a psychedelic stock is legit or full of shit?  This video describes how to research and understand both the psychedelic sector as a whole and individual psychedelic companies.  First we walk through my notes on investing in the psychedelic sector, and then look at 10 questions you should ask before investing in any psychedelic company.  We show how to use these questions to compare and contrast different psychedelic companies, and apply this methodology to Mind Medicine, Compass Pathways and Cybin.    

My notes on psychedelic investing: https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf   

Google Spreadsheet containing the 10 questions: 

https://docs.google.com/spreadsheets/d/1KIp_nd-OhyU5xx63oEMsKgU3XFZkkItl-aoyjCdItkg/edit?usp=sharing    

CLARIFICATIONS / CORRECTIONS 

📺 Watch on YouTube:  https://youtu.be/oA85Xzms8_U

🎇 Clips and other stuff on Instagram:  https://instagram.com/bromtalks​​  

🐦 brom on twitter: https://twitter.com/therealbrom​​  

⏰Timestamps:   

Disclaimer: This presentation is not financial advice.  You should not make any investment or trading decision based on the contents of this presentation.  Do not consider anything in this presentation to be professional advice.  Brom holds long positions in MindMed, Compass and Cybin as well as other psychedelic stocks.